Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2024-09-12 Share Issue/Capital Cha…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing a 'directed issue of units' to guarantors as compensation for a previously completed rights issue. It details the number of shares, warrants, subscription prices, and the impact on share capital and dilution. This falls under the category of share issuance and capital structure changes, specifically related to the company's own shares and capital adjustments.
2024-09-12 English
Immunovia genomför en riktad emission av units till garanter i samband med den genomförda företrädesemissionen
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing a 'directed issue of units' (a form of share issuance) to guarantors as compensation for their role in a previous rights issue. It details the number of units, subscription price, dilution effects, and the rationale for the issuance. This falls under the category of share issuance and capital changes, which is classified as 'SHA'.
2024-09-12 Swedish
Immunovia offentliggör slutligt utfall i företrädesemission
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing the final outcome of a rights issue (företrädesemission). It details the subscription levels, the number of units issued, the impact on share capital, and the timeline for the issuance of shares and warrants. This falls under the category of announcements regarding new share issues and capital changes.
2024-09-03 Swedish
Immunovia announces final outcome in rights issue
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the final outcome of a rights issue (a capital raising event). It details the subscription percentages, the amount of capital raised, the impact on share capital, and the issuance of warrants. This falls under the category of capital and financing updates, as it describes the results of a specific financing activity.
2024-09-03 English
Immunovia offentliggör preliminärt utfall i företrädesemission
Capital/Financing Update Classification · 1% confidence The document is a press release ("PRESSMEDDELANDE") from Immunovia AB dated September 2, 2024, announcing the preliminary outcome of a rights issue ("företrädesemission"). This announcement details the subscription rate (91.2%) and confirms that guarantee commitments will not be utilized. This type of announcement, concerning fundraising, capital structure changes, and the results of a subscription period for new securities (units consisting of shares and warrants), directly aligns with the definition of a Capital/Financing Update. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific announcement about a financing event, the most appropriate code is CAP (Capital/Financing Update). It is not merely an announcement of a report (RPA/RNS), as it contains substantive, time-sensitive financial/corporate action results.
2024-09-02 Swedish
Immunovia publishes preliminary outcome in rights issue
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "preliminary outcome in rights issue." A rights issue is a form of capital fundraising activity where existing shareholders are given the right to purchase additional new shares. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it relates to a prospectus, the document itself is the announcement of the subscription results, not the prospectus or the final report itself. Therefore, CAP is the most appropriate classification.
2024-09-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.